Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 01)
Nufymco Injection, Solution
Product Images NDC 70710-2172
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Nufymco (NDC 70710-2172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 02)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 03)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 04)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 05)
This is a small volume of 0.05 milliliters. It is often used in precise measurements for liquids or substances.*
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 06)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 07)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 08)
This is a statistical report comparing the impact on visual acuity between two treatments, Ranibizumab 0.5 mg monthly and Ranibizumab 0.5 mg less frequent than monthly. The study involves a total of 275 participants.*
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 09)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 10)
This text provides information about the mean change in visual acuity. The data seems to include factors related to visual acuity and mentions points related to measurement.*
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 11)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 12)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 13)
Image (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 14)
Ranibizumab-leyk Injection, 0.3 mg (0.05 mL Of 6 mg/ml Solution) (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 15)
This is a detailed description of a medication called Nufymco™ used for intravitreal injection only. It is indicated for treating diabetic macular edema (DME) and diabetic retinopathy (DR). Each single-dose vial contains 0.3 mg of ranibizumab-leyk in a 6 mg/mL solution. The medication is manufactured by Formycon AG in Germany and distributed by Zydus Pharmaceuticals (USA) Inc. The vials are designed to deliver 0.05 mL of the solution, which contains histidine HCI, a,c-trehalose dihydrate, and polysorbate 20. It does not contain any preservatives and should be refrigerated between 2°C to 8°C. The packaging includes prescribing information and precautions to keep the medication out of reach of children, avoid freezing, and protect from light.*
Ranibizumab-leyk Injection, 0.5 mg (0.05 mL Of 10 mg/ml Solution) (4a45dd5a C8d9 4e98 9586 Ab6c069c2ffe 16)
Nufymco™ (ranibizumab-leyk) injection is a medication indicated for various eye conditions like neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It comes in a single-dose vial designed for intravitreal injection only. The solution contains 0.5 mg of ranibizumab-leyk and specific ingredients. The product is distributed by Zydus Pharmaceuticals in the USA and must be stored refrigerated at 2°C to 8°C. Detailed prescribing information is available, and caution is advised to keep the product out of reach of children and protect it from freezing and light exposure.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
